LIXTE Biotech Enters Material Definitive Agreement
Ticker: LIXT · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1335105
Sentiment: neutral
Topics: material-agreement, corporate-action
Related Tickers: LIXT
TL;DR
**LIXT just inked a material definitive agreement, likely involving stock and warrants, on Feb 23rd!**
AI Summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) filed an 8-K on February 26, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on February 23, 2024. The filing indicates a transaction involving common stock and warrants to purchase common stock, with the company's business address listed as 680 East Colorado Blvd. Suite 180 Pasadena, California 91101.
Why It Matters
This filing signals a significant corporate action for LIXTE BIOTECHNOLOGY HOLDINGS, INC., potentially impacting its capital structure and future financing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement without specific financial details, which could introduce uncertainty regarding its impact.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filing registrant
- February 23, 2024 (date) — Date of earliest event reported
- February 26, 2024 (date) — Filing date
- 001-39717 (other) — Commission File Number
- 680 East Colorado Blvd. Suite 180 Pasadena, California 91101 (other) — Principal executive offices address
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 23, 2024.
What type of agreement did LIXTE BIOTECHNOLOGY HOLDINGS, INC. enter into?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into a "Material Definitive Agreement" as reported in Item 1.01 of the 8-K.
What is the Commission File Number for LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
The Commission File Number for LIXTE BIOTECHNOLOGY HOLDINGS, INC. is 001-39717.
Where are LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s principal executive offices located?
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s principal executive offices are located at 680 East Colorado Blvd. Suite 180 Pasadena, California 91101.
What items were reported in this 8-K filing?
This 8-K filing reported "Entry into a Material Definitive Agreement," "Other Events," and "Financial Statements and Exhibits."
Filing Stats: 963 words · 4 min read · ~3 pages · Grade level 13.6 · Accepted 2024-02-26 10:48:13
Key Financial Figures
- $50,000 — non-refundable license issue royalty of $50,000 and a first minimum annual royalty of $
- $30,000 — 0 and a first minimum annual royalty of $30,000, within sixty days from the effective d
- $1,225,000 — total of all such benchmark payments is $1,225,000. The Company is obligated to pay the
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 431KB
- ex99-1.htm (EX-99.1) — 14KB
- ex10-1_001.jpg (GRAPHIC) — 23KB
- ex10-1_002.jpg (GRAPHIC) — 34KB
- ex10-1_003.jpg (GRAPHIC) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001493152-24-007784.txt ( ) — 853KB
- lixt-20240223.xsd (EX-101.SCH) — 3KB
- lixt-20240223_def.xml (EX-101.DEF) — 26KB
- lixt-20240223_lab.xml (EX-101.LAB) — 36KB
- lixt-20240223_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 26, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan President and Chief Executive Officer -3- INDEX TO EXHIBITS Exhibit No. Description 10.1 Exclusive Patent License with NINDS and NCI 99.1 Press Release announcing entering into the License Agreement with NINDS and NCI 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) -4-